PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant decrease in short interest during the month of December. As of December 30th, there was short interest totalling 200 shares, a decrease of 50.0% from the December 15th total of 400 shares. Based on an average daily volume of 1,900 shares, the short-interest ratio is currently 0.1 days.
Institutional Investors Weigh In On PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. grew its position in PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after acquiring an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.25% of the company's stock.
Get PureTech Health alerts:PureTech Health Price Performance
Shares of PRTC stock traded up $0.05 during trading hours on Wednesday, hitting $29.54. The stock had a trading volume of 703 shares, compared to its average volume of 402. PureTech Health has a twelve month low of $18.15 and a twelve month high of $43.57. The stock's 50 day moving average is $31.96 and its 200 day moving average is $28.58.
About PureTech Health
(Get Rating)PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
See Also
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Can Alaska Air Continue Soaring Above The Airline Industry?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.